Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations in Insulin Resistance

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-65
SponsorAdventHealth Translational Research Institute

About this trial

The purpose of this study is to find new signs or signals in muscle cells that can help us understand when the body isn't responding well to insulin (a condition called insulin resistance).

Eligibility criteria

Qualifiers

All Groups

30 to 65 years of age

Stable weight (No Gain/Loss of >10 lbs in 6 months)

Sedentary (≤ 1 continuous exercise/week)

Disqualifiers

Clinically significant CVD including h/o MI, within the past year

Peripheral Vascular Disease

Diagnosed with Type I or Type II diabetes

Hepatic, renal, muscular/neuromuscular, or active hematologic/oncologic disease

Trial design

Treatments tested in this trial

  • VO2 Max
  • DEXA
  • Peripheral Microvascular Reactivity
  • Skeletal Muscle Insulin Sensitivity
  • Non-Oxidative Glucose Disposal
  • Muscle tissue Biopsy

Treatment groups

36 Participants
are divided into 3 treatment groups

Sponsors and collaborators

AdventHealth Translational Research Institute

Lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator